|
|
||||||||||||||
|
|
|||||||||||||||
1 John Radcliffe Hospital, Oxford, UK
2 Chefarzt, Abteilung für Innere Medizin 1 Schwerpunkte Gastroenterologie, Hepatologie und Endokrinologie, Robert Bosch Krankenhaus, Stuttgart, Germany
3 Service de Gastroentérologie, Hôpital Saint-Louis, Paris, France
4 Colorectal Unit, Department of Surgery, Sahlgrenska Universiteitssjukhuset/Östra, Gothenburg, Sweden
5 Chaim Sheba Medical Center, Tel Hashomer, Israel 52621
6 University College Hospital, London, UK
7 Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
8 Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
9 Department of Gastroenterology, University Hospital, Lille, France
10 Azienda Ospedaliera S. Camillo-Forlanini, Unita Operativa di Gastroenterologia, Rome, Italy
11 Hospital Européen Department of Gastroenterology, Paris, France
12 Hospital Huriez, Department of HepatoGastroenterology, CH et U, Lille, France
13 Universita di Bologna, Bologna, Italy
14 Hospital Lariboisière, Department of Gastroenterology, Paris, France
15 Inserm, Paris, France, and Universite Pierre et Marie Curie, Paris, France
16 Chirurgische Klinik I (Allgemein-, Gefäß- und Thoraxchirurgie), Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany
17 Institute of Pathology, University of Graz, Austria
18 Department of Colorectal Surgery, John Radcliffe, Oxford, UK
Correspondence to:
Correspondence to:
Dr S P L Travis
John Radcliffe Hospital, Oxford OX3 9DU, UK; simon.travis{at}orh.nhs.uk; Professor E F Stange, Department of Internal Medicine 1, Robert Bosch Krankenhaus, PO Box 501120, Auerbachstr 110, 70341 Stuttgart, Germany; Eduard.Stange{at}rbk.de
ABSTRACT
This second section of the European Crohns and Colitis Organisation (ECCO) Consensus on the management of Crohns disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohns disease. The third section on special situations in Crohns disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohns disease.
Abbreviations: 5-ASA, mesalazine; AZA, azathioprine; CD, Crohns disease; CDAI, Crohns disease activity index; CRP, C reactive protein; CsA, cyclosporin; ECCO, European Crohns and Colitis Organisation; ESR, erythrocyte sedimentation rate; IBD, inflammatory bowel disease; IFX, infliximab; MTX, methotrexate; 6-MP, 6-mercaptopurine; NNH, number needed to harm; NNT, number needed to treat; UC, ulcerative colitis
Keywords: Crohns disease; treatment; mesalazine; corticosteroids; azathioprine; infliximab; surgery
This article has been cited by other articles:
![]() |
N. Fujita, T. Itoh, H. Omori, M. Fukuda, T. Noda, and T. Yoshimori The Atg16L Complex Specifies the Site of LC3 Lipidation for Membrane Biogenesis in Autophagy Mol. Biol. Cell, May 1, 2008; 19(5): 2092 - 2100. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Shin and M. T. Collins Thiopurine Drugs Azathioprine and 6-Mercaptopurine Inhibit Mycobacterium paratuberculosis Growth In Vitro Antimicrob. Agents Chemother., February 1, 2008; 52(2): 418 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Cassinotti, C Annaloro, S Ardizzone, F Onida, A D. Volpe, M Clerici, P Usardi, S Greco, G Maconi, G B. Porro, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease Gut, February 1, 2008; 57(2): 211 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Salar, X. Bessa, E. Muniz, D. Monfort, C. Besses, and M. Andreu Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease Gut, August 1, 2007; 56(8): 1169 - 1170. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |